论文部分内容阅读
目的观察噻托溴铵、舒利迭和多索茶碱联合治疗中-重度COPD的临床疗效。方法选取中重度COPD稳定期患者30例,随机分为三组,A组给予噻托溴铵;B组给予噻托溴铵及舒利迭;C组给予噻托溴铵,舒利迭及多索茶碱。疗程均为24周。治疗前后测量肺功能,同期采用圣乔治呼吸问题调查问卷(SGRQ)评价生活质量。结果噻托溴铵、舒利迭和多索茶碱联合治疗组治疗后较其他组治疗后肺功能改善更为显著,生活质量显著提高。结论噻托溴铵、舒利迭和多索茶碱联合能有效治疗稳定期中-重度COPD患者。
Objective To observe the clinical efficacy of tiotropium, seretide and doxofylline in the treatment of moderate-severe COPD. Methods Thirty patients with moderate to severe COPD were randomly divided into three groups: group A received tiotropium; group B received tiotropium and seretide; group C received tiotropium, seretide and more Sofylline. The course of treatment was 24 weeks. The lung function was measured before and after treatment, and the quality of life was evaluated by St George’s Respiratory Questionnaire (SGRQ) during the same period. Results After treatment with tiotropium, seretide and doxofylline, pulmonary function improved more significantly than those in other groups, and the quality of life was significantly improved. Conclusion The combination of tiotropium, seretide and doxofylline can effectively treat stable moderate-severe COPD patients.